Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Notes Payables (2018 - 2025)

China SXT Pharmaceuticals has reported Notes Payables over the past 8 years, most recently at $976367.0 for Q3 2025.

  • For Q3 2025, Notes Payables rose 17.93% year-over-year to $976367.0; the TTM value through Sep 2025 reached $976367.0, up 17.93%, while the annual FY2025 figure was $702184.0, 42.42% up from the prior year.
  • Notes Payables for Q3 2025 was $976367.0 at China SXT Pharmaceuticals, up from $702184.0 in the prior quarter.
  • Over five years, Notes Payables peaked at $976367.0 in Q3 2025 and troughed at -$7675.0 in Q3 2022.
  • A 5-year average of $387526.1 and a median of $267270.0 in 2023 define the central range for Notes Payables.
  • Biggest five-year swings in Notes Payables: tumbled 131.92% in 2022 and later skyrocketed 3582.35% in 2023.
  • Year by year, Notes Payables stood at $24042.0 in 2021, then tumbled by 131.92% to -$7675.0 in 2022, then skyrocketed by 3582.35% to $267270.0 in 2023, then surged by 209.77% to $827918.0 in 2024, then rose by 17.93% to $976367.0 in 2025.
  • Business Quant data shows Notes Payables for SXTC at $976367.0 in Q3 2025, $702184.0 in Q1 2025, and $827918.0 in Q3 2024.